GSK welcomes the publication of the 2012 Access to Medicines Index
- Details
- Category: GlaxoSmithKline
GSK welcomes the publication of the third Access to Medicines (ATM) Index, which measures the performance of the top 20 pharmaceutical companies on their efforts to improve access to medicines and healthcare in developing countries. GSK has been ranked top of the Index in 2012 for the third time of publishing,
Sanofi ranks third on the Access to Medicine Foundation's 2012 ATM Index
- Details
- Category: Sanofi
Sanofi (EURONEXT: SAN and NYSE: SNY) ranked third among twenty pharmaceutical companies on the 2012 Access to Medicine Index (ATM Index) created by the Access to Medicine Foundation, an international non-profit organization dedicated to improving access to medicine to societies in need.
Novartis highlights key data in patients with hematologic diseases and breast cancer
- Details
- Category: Novartis
Novartis will highlight more than 140 presentations on key data from its extensive oncology portfolio at the leading year-end scientific meetings devoted to hematology and breast cancer, demonstrating continued innovation in research and development efforts to advance the care of patients with cancer and rare diseases.
Novartis receives FDA approval for Flucelvax®
- Details
- Category: Novartis
Novartis announced that the US Food and Drug Administration (FDA) approved the use of Flucelvax® (Influenza Virus Vaccine), the first cell-culture-derived vaccine, for individuals 18 years of age and older[3]. Flucelvax utilizes full-scale cell-culture manufacturing technology, an alternative production method to traditional egg-based production[1].
Shire and Boston Children's Hospital enter into broad research collaboration
- Details
- Category: Shire
Shire plc (LSE: SHP, NASDAQ: SHPG) and Boston Children's Hospital today announced a three-year, broad research collaboration in rare diseases. The goal of the collaboration is to develop novel therapies to treat a number of rare pediatric diseases with high unmet medical need, thereby leveraging Boston Children's research expertise and Shire's development and commercialization capabilities.
Results from the positive phase III AVAglio study
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced results from the positive phase III AVAglio study. The study showed Avastin (bevacizumab) in combination with radiation and temozolomide chemotherapy reduced the risk of cancer worsening or death (progression-free survival; PFS) by 36 percent compared to radiation and temozolomide chemotherapy plus placebo (HR=0.64; p<0.0001) in people with newly diagnosed glioblastoma,
Bayer's "Perspective on Innovation 2012"
- Details
- Category: Bayer
With numerous new products, the Bayer Group aims to help improve people's lives while exploiting billions in potential sales. "Innovation is the only way to address the global challenges that exist at the beginning of the third millennium," Management Board Chairman Dr. Marijn Dekkers said on Wednesday, addressing some 140 journalists at Bayer's "Perspective on Innovation 2012" forum in Leverkusen.
More Pharma News ...
- Sanofi and T1D Exchange to launch worldwide study
- Bristol-Myers Squibb Foundation's Together on Diabetes™ marks World Diabetes Day
- The largest clinical study of Bayer's Xarelto® (rivaroxaban)
- Boehringer Ingelheim enters strategic collaboration agreement to support Molecular Partner's proprietary pipeline
- Novartis future growth prospects secured by industry-leading pipeline
- Results from the largest known cholesterol survey conducted in the U.S.
- Portola, Bristol-Myers Squibb and Pfizer sign clinical collaboration agreement to study ELIQUIS® and Portola's universal Factor Xa inhibitor antidote PRT4445